Filing Flows › Lyell Immunopharma (LYEL) › Q3 2026 › vs Q3 2025
Lyell Immunopharma (LYEL) Q3 2026 vs Q3 2025 (year over year)
Lyell Immunopharma's revenue fell $12K (-80%) from $15K in Q3 2025 to $3K in Q3 2026.
Lyell Immunopharma, Q3 2026: revenue $3K (-80% year over year), net loss $45.5M, operating cash flow −$34.6M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $3K | $15K | −$12K | -80% |
| Other income, net | $2.8M | −$1.6M | $4.4M | — |
| Net loss | $45.5M | $38.8M | $6.7M | +17% |
| Costs & expenses | $48.3M | $38.9M | $9.4M | +24% |
| Operating costs | $48.3M | $37.3M | $11.0M | +30% |
| Operating cash sources | $45.5M | $38.8M | $6.7M | +17% |
| Depreciation & amortization | $2.1M | $2.6M | −$512K | -20% |
| Share-based compensation | $4.5M | $5.2M | −$718K | -14% |
| Working capital & other | $4.4M | $2.5M | $1.9M | +78% |
| Cash used in operations | $34.6M | $28.6M | $6.0M | +21% |
| Net loss absorbed | $45.5M | $38.8M | $6.7M | +17% |
Questions
How much did Lyell Immunopharma's revenue grow year over year in Q3 2026?
Lyell Immunopharma's revenue fell $12K (-80%) from $15K in Q3 2025 to $3K in Q3 2026.